Pneumococcal vaccination and revaccination in the elderly population

Affiliations

Comment

Kristin L Nichol. J Infect Dis. 2010 Mar.

. 2010 Mar;201(5):659-61.

doi: 10.1086/651376.

¹ Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis, USA. Nicho014@umn.edu

No abstract available

Comment on

Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, Carlone GM. Manoff SB, et al. J Infect Dis. 2010 Feb 15;201(4):525-33. doi: 10.1086/651131. J Infect Dis. 2010. PMID: 20088694 Clinical Trial.
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Musher DM, et al. J Infect Dis. 2010 Feb 15;201(4):516-24. doi: 10.1086/649839. J Infect Dis. 2010. PMID: 20092407 Clinical Trial.